论文部分内容阅读
目的探讨恶性淋巴瘤中细胞外基质金属蛋白酶诱导因子(EMMPRIN)的表达及其与基质金属蛋白酶(MMPs)表达和疾病进展的关系。方法运用实时定量PCR法检测了81例恶性淋巴瘤患者淋巴瘤组织中EMMPRIN、MMP-2和MMP-9的表达。同时通过电镜对淋巴瘤组织切片中肿瘤浸润血管情况进行观察。结果与淋巴结反应性增生(8例)相比,不同类型的恶性淋巴瘤均高表达EMMPRIN、MMP-2和MMP-9。EMMPRIN来自淋巴瘤细胞。Ann Arbor分期为III-IV、伴多个淋巴结外病变和国际预后指数分组为高危组的患者上述基因的表达水平显著升高。此外,EMM-PRIN、MMP-2和MMP-9高表达者可见淋巴瘤细胞浸润血管。结论EMMPRIN表达可促进恶性淋巴瘤MMPs的表达,并与疾病进展密切相关。
Objective To investigate the expression of extracellular matrix metalloproteinase inducer (EMMPRIN) in malignant lymphoma and its relationship with the expression of matrix metalloproteinases (MMPs) and disease progression. Methods The expression of EMMPRIN, MMP-2 and MMP-9 in lymphoma tissues from 81 patients with malignant lymphoma were detected by real-time PCR. At the same time by electron microscopy of lymphoma tissue sections of tumor infiltration of blood vessels were observed. Results Compared with reactive hyperplasia of lymph nodes (n = 8), EMMPRIN, MMP-2 and MMP-9 were highly expressed in different types of malignant lymphoma. EMMPRIN is from lymphoma cells. Ann Arbor stage III-IV, with multiple extranodal lesions and international prognostic index grouping for the high-risk group of patients with significantly increased expression of the above genes. In addition, lymphoma cells infiltrated blood vessels in patients with high expression of EMM-PRIN, MMP-2 and MMP-9. Conclusion EMMPRIN expression can promote the expression of MMPs in malignant lymphoma and is closely related to the progress of the disease.